ethyl (E)-3-{3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl}acrylate | 1018438-90-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (E)-3-{3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl}acrylate
• 英文别名: (E)-ethyl 3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate；(E)-3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)-3-methoxyphenyl)acrylic acid ethyl ester；(e)-3-(4-((3,5,6-Trimethylpyrazin-2-yl) methoxy)-3-methoxyphenyl)acrylic acid ethyl ester；ethyl (E)-3-[3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl]prop-2-enoate
• CAS: 1018438-90-8
• 化学式: C₂₀H₂₄N₂O₄
• 分子量: 356.422
• InChiKey: NTZAXVRLBTXSNU-CSKARUKUSA-N

物化性质

• 熔点：
  104-108 °C(Solv: hexane (110-54-3))
• 沸点：
  497.9±40.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  70.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl (E)-3-{3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl}acrylate 在 水 、 间氯过氧苯甲酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 14.0h， 生成
  参考文献：
  名称：

  吡拉格雷钠代谢物及其制备方法

  摘要：

  本发明涉及药物合成领域，具体涉及一种吡拉格雷钠代谢物(I)及其制备方法。本发明吡拉格雷钠又一代谢产物的发明为吡拉格雷钠临床药物体内代谢研究提供了多种方法和依据，且制备得到该代谢产物可以为代谢研究提供对照样品。

  公开号：

  CN109553582A
• 作为产物：
  描述：

  阿魏酸 在 氯化亚砜 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 ethyl (E)-3-{3-methoxy-4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl}acrylate
  参考文献：
  名称：

  Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents

  摘要：

  A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC50=0.020 mM), and compound 2f was the most active anti-platelet aggregation agent (EC50=0.054 mM). Structure activity relationships were briefly discussed. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.09.030

文献信息

• Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application
  申请人：Li Jiaming

  公开号：US20100228029A1

  公开（公告）日：2010-09-09

  Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.

  利血平芳香酸醚衍生物I的通式，其制备方法，药物组成和应用，其中Ar选自芳基取代芳基和取代苯乙烯基，R选自氢和不超过6个碳原子的烷基。
• 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives
  申请人：——

  公开号：US08350033B2

  公开（公告）日：2013-01-08

  Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.

  Ligustrazine芳香酸醚衍生物的一般式I，其制备方法，药物组合物和应用，其中Ar选自取代芳基和取代苯乙烯基，R选自氢和不超过6个碳原子的烷基。
• LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION
  申请人：Li, Jiaming

  公开号：EP2213666B1

  公开（公告）日：2012-02-15
• US8350033B2
  申请人：——

  公开号：US8350033B2

  公开（公告）日：2013-01-08
• Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents
  作者：Hongfei Chen、Guoning Li、Peng Zhan、Xinyong Liu

  DOI：10.1016/j.ejmech.2011.09.030

  日期：2011.11

  A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC50=0.020 mM), and compound 2f was the most active anti-platelet aggregation agent (EC50=0.054 mM). Structure activity relationships were briefly discussed. (C) 2011 Elsevier Masson SAS. All rights reserved.